All In Biotech

Drug Trial Radar · NCT05546853

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Mar 28, 2023

Primary completion

Dec 9, 2024

Study completion Jun 16, 2025

Sponsor

Lead sponsor
University Hospital, GrenobleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NETRIS Pharma
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will assess the safety of the association of NP137 with the standard of care mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association with mFOLFIRINOX to allow a better tumor response as well as better survival outcomes with an acceptable safety.

Conditions

  • Pancreatic Ductal Adenocarcinoma

Interventions

  • NP137Drug

    NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.

  • OxaliplatinDrug

    Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²

  • IrinotecanDrug

    Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²

  • Calcium levofolinateDrug

    Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²

  • 5 FUDrug

    5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Proportion of patients experiencing adverse eventsTime frame: At 6 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de BORDEAUX

    Bordeaux, France

  • CHRU Lille

    Lille, France

  • Hôpital Privé Jean Mermoz

    Lyon, France

  • AP-HP Pitié Salpetrière

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • CHU de REIMS

    Reims, France

  • CHU Rennes

    Rennes, France

  • CHU St Etienne

    Saint-Etienne, France

  • CHU de GRENOBLE ALPES

    Grenoble, Alpes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.